Six-month outcomes for patients who switched to olanzapine treatment

Psychiatric Services

Volumn 52, Issue 4, 2001, Pages 501-507

  Noordsy, D L ^a   O'Keefe, C ^a   Mueser, K T ^a   Xie, H ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSYCHOSIS; RELAPSE; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; CHLORPROMAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PIRENZEPINE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035072549     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.52.4.501     Document Type: Article

References (34)

1. Diagnosis of alcohol use disorders in schizophrenia
2. Prevalence of infection with HIV among the seriously mentally ill: Review of the research and implications for practice
3. Complications of severe mental illness related to alcohol and other drug use disorders
4. Models of community care for severe mental illness: A review of research on case management
5. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
6. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
7. Treatment costs and patient outcomes with use of risperidone in a public mental health setting
8. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a CMHC setting
9. Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia
10. Assessment of enduring negative symptom subtypes in schizophrenia
11. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison versus chlorpromazine/benztropine
12. Risperidone in the treatment of schizophrenia
13. Olanzapine versus haloperidol in the treatment of schizophrenia and schizophreniform disorders: Results of an international collaborative trial
14. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
15. Does participation in psychosocial treatment augment the benefit of clozapine?
16. Integrating dialectical behavioral therapy into a community mental health program
17. Recovery-oriented pharmacology: Redefining the goals of antipsychotic treatment
18. Community support systems for persons with long-term mental illness: A conceptual framework
19. Brief history, current status, and future place of PACT
20. An update on supported employment for people with severe mental illness
21. New developments in social skills training
22. Integrated mental health and substance abuse treatment for severe psychiatric disorders
23. A clinical trial of assertive community treatment for patients with co-occurring severe mental illness and substance use disorder
24. Negative symptoms in schizophrenia
25. Housing instability and homelessness among aftercare patients of an urban state hospital
26. Substance abuse among the chronic mentally ill
27. Alcohol use and abuse in schizophrenia: A prospective community study
28. Methodologic issues in assertive community treatment studies
29. Six-month outcomes for patients switched to olanzapine in community psychiatric care
30. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
31. Long-term consideration after switching antipsychotics